BFLY vs. LMAT, NVCR, EYE, ENOV, CNMD, TNDM, CDRE, AORT, LQDA, and FNA
Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include LeMaitre Vascular (LMAT), NovoCure (NVCR), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Tandem Diabetes Care (TNDM), Cadre (CDRE), Artivion (AORT), Liquidia Technologies (LQDA), and Paragon 28 (FNA). These companies are all part of the "medical equipment" industry.
Butterfly Network vs. Its Competitors
LeMaitre Vascular (NASDAQ:LMAT) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
In the previous week, Butterfly Network had 6 more articles in the media than LeMaitre Vascular. MarketBeat recorded 7 mentions for Butterfly Network and 1 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.73 beat Butterfly Network's score of 0.34 indicating that LeMaitre Vascular is being referred to more favorably in the media.
LeMaitre Vascular has a net margin of 19.96% compared to Butterfly Network's net margin of -75.56%. LeMaitre Vascular's return on equity of 13.53% beat Butterfly Network's return on equity.
LeMaitre Vascular has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
LeMaitre Vascular presently has a consensus target price of $97.83, suggesting a potential upside of 15.90%. Butterfly Network has a consensus target price of $3.50, suggesting a potential upside of 75.44%. Given Butterfly Network's stronger consensus rating and higher possible upside, analysts clearly believe Butterfly Network is more favorable than LeMaitre Vascular.
LeMaitre Vascular has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 9.5% of LeMaitre Vascular shares are held by insiders. Comparatively, 25.2% of Butterfly Network shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
LeMaitre Vascular beats Butterfly Network on 10 of the 16 factors compared between the two stocks.
Get Butterfly Network News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFLY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Butterfly Network Competitors List
Related Companies and Tools
This page (NYSE:BFLY) was last updated on 7/5/2025 by MarketBeat.com Staff
Free BFLY Stock Alerts